Recent Updates
Recently added Catalysts
NAGE Positive Sentiment Score: 75/100

Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging

Key Takeaway: Niagen Bioscience, Inc. has announced the publication of a peer-reviewed analysis in Aging Cell, highlighting the positive effects of Niagen® (nicotinamide riboside) supplementation. The study indicates that this supplementation is associated with a reduction in muscle epigenetic age acceleration, as measured by the Muscle Epigenetic Age Test (MEAT) clock. This finding supports the potential of Niagen® in promoting healthy aging.

Market Sentiment Analysis

POSITIVE FACTORS

  • New peer-reviewed analysis published in Aging Cell.
  • Niagen® supplementation shows promise in reducing biological aging.
  • Results indicate improved muscle-specific aging markers.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BiologicalAge--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® (patented nicotinamide riboside, NR) supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock. In additi

Frequently Asked Questions

What is Niagen®?

Niagen® is a patented form of nicotinamide riboside, a supplement aimed at promoting healthy aging.

What did the new study analyze?

The study analyzed past clinical studies to assess the effects of Niagen® on biological aging.

How does Niagen® affect muscle aging?

Niagen® supplementation was associated with reduced muscle epigenetic age acceleration.

Where was the study published?

The analysis was published in the peer-reviewed journal Aging Cell.

Last updated: Jul 28, 2026